Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.

Armenian SH, Hudson MM, Chen MH, Colan SD, Lindenfeld L, Mills G, Siyahian A, Gelehrter S, Dang H, Hein W, Green DM, Robison LL, Wong FL, Douglas PS, Bhatia S.

BMC Cardiovasc Disord. 2016 Oct 4;16(1):187.

2.

Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study.

Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K.

CMAJ Open. 2016 Feb 18;4(1):E66-72. doi: 10.9778/cmajo.20150033. eCollection 2016 Jan-Mar.

3.

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC; CPNDS Clinical Practice Recommendations Group..

Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30. Review.

PMID:
27197003
4.

Clinical Characteristics and Treatment of Cardiomyopathies in Children.

Price JF, Jeewa A, Denfield SW.

Curr Cardiol Rev. 2016;12(2):85-98. Review.

PMID:
26926296
5.

Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.

Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, Butler J.

Circ Heart Fail. 2016 Feb;9(2):e002843. doi: 10.1161/CIRCHEARTFAILURE.115.002843. Review.

6.

Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.

Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, Butler J.

Circ Heart Fail. 2016 Jan;9(1):e002661. doi: 10.1161/CIRCHEARTFAILURE.115.002661. Review.

7.

Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer.

Armstrong GT, Ross JD.

Prog Pediatr Cardiol. 2014 Sep 1;36(1-2):19-26.

8.

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, Nathan PC, Tissing WJ, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen EC, van der Pal H, Wallace WH, Levitt G, Kremer LC; International Late Effects of Childhood Cancer Guideline Harmonization Group..

Lancet Oncol. 2015 Mar;16(3):e123-36. doi: 10.1016/S1470-2045(14)70409-7. Review.

9.

Cardiovascular disease in adult survivors of childhood cancer.

Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE.

Annu Rev Med. 2015;66:161-76. doi: 10.1146/annurev-med-070213-054849. Review.

10.

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P.

Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93. doi: 10.1093/ehjci/jeu192. No abstract available.

11.

Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M.

Mayo Clin Proc. 2014 Sep;89(9):1287-306. doi: 10.1016/j.mayocp.2014.05.013. Review.

12.

Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.

Sisakian H.

World J Cardiol. 2014 Jun 26;6(6):478-94. doi: 10.4330/wjc.v6.i6.478. Review.

13.

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.

Wong FL, Bhatia S, Landier W, Francisco L, Leisenring W, Hudson MM, Armstrong GT, Mertens A, Stovall M, Robison LL, Lyman GH, Lipshultz SE, Armenian SH.

Ann Intern Med. 2014 May 20;160(10):672-83. doi: 10.7326/M13-2498.

15.

Milestones in the curability of pediatric cancers.

Hudson MM, Link MP, Simone JV.

J Clin Oncol. 2014 Aug 10;32(23):2391-7. doi: 10.1200/JCO.2014.55.6571. Epub 2014 Apr 14. No abstract available.

16.

Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness.

Eckman DM, Stacey RB, Rowe R, D'Agostino R Jr, Kock ND, Sane DC, Torti FM, Yeboah J, Workman S, Lane KS, Hundley WG.

PLoS One. 2013;8(2):e57554. doi: 10.1371/journal.pone.0057554. Epub 2013 Feb 21.

17.

Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.

Armenian SH, Gelehrter SK, Chow EJ.

Cardiol Res Pract. 2012;2012:713294. doi: 10.1155/2012/713294. Epub 2012 Aug 15.

18.

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE.

Future Cardiol. 2012 Jul;8(4):647-70. doi: 10.2217/fca.12.44. Review.

19.

Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.

Goldberg JM, Scully RE, Sallan SE, Lipshultz SE.

J Pediatr Hematol Oncol. 2012 Jul;34(5):395-7. doi: 10.1097/MPH.0b013e3182532078.

20.

Cardio-oncology: a new medical issue.

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Pandini C, Sandri MT, Cipolla CM.

Ecancermedicalscience. 2008;2:126. doi: 10.3332/ecancer.2008.126. Epub 2008 Dec 15.

Supplemental Content

Support Center